SCHEMBL685901

SCHEMBL685901

C=Cc1ccc(O)c(C(=O)OC)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.67
CA12 O43570 3/20 0.61
CA1 P00915 3/20 0.61
CA2 P00918 3/20 0.61
CA7 P43166 3/20 0.61
CA9 Q16790 3/20 0.61
CA14 Q9ULX7 3/20 0.61
TRPA1 O75762 1/20 0.54
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
PTGS1 P23219 1/20 0.49
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
PTPN1 P18031 2/20 0.47
PDK2 Q15119 1/20 0.47
PDK4 Q16654 1/20 0.47
GAA P10253 1/20 0.45
EGFR P00533 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL685071 0.86 CA12 (0.61) PTGS2CA12CA1CA2CA7
SCHEMBL3892038 0.86 PTGS2 (0.49) PTGS2CA12CA1CA2CA7
SCHEMBL30263061 0.86 PTGS2 (0.49) PTGS2CA12CA1CA2CA7
SCHEMBL853107 0.84 PTGS2 (0.69) PTGS2CA12CA1CA2CA7
SCHEMBL13926061 0.84 PTGS2 (0.84) PTGS2CA12CA1CA2CA7
SCHEMBL16069338 0.83 PTGS2 (0.46) PTGS2CA12CA1CA2CA7
SCHEMBL23812340 0.82 EGFR (0.47) PTGS2CA12CA1CA2CA7
SCHEMBL8073599 0.82 CA12 (0.64) PTGS2CA12CA1CA2CA7
SCHEMBL31124129 0.82 EGFR (0.47) PTGS2CA12CA1CA2CA7
SCHEMBL11922585 0.81 PTGS2 (0.45) PTGS2CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230305398-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-28 US disclosed
US-20230305398-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-28 US disclosed
US-10377692-B2 Photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-08-13 US disclosed
US-9726976-B2 Photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-08 US disclosed
US-9726976-B2 Photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-08 US disclosed
US-9405187-B2 Salt, acid generator and resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-02 US disclosed
US-9405187-B2 Salt, acid generator and resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-02 US disclosed
US-9346750-B2 Salt and photoresist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-05-24 US disclosed
US-9346750-B2 Salt and photoresist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-05-24 US disclosed
US-9229320-B2 Resist composition and method for producing resist pattern SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-01-05 US disclosed
US-5556855-A TREATMENT OF AUTOIMMUNE DISEASES PHARMACIA AB (SE) 1996-09-17 US disclosed
US-5403930-A Chemical intermediate for drugs used in autoimmune diseases PHARMACIA AB (SE) 1995-04-04 US disclosed
EP-0457332-B1 Polymerizable carbonates having ethylenic and acetylenic functions NIPPON PAINT CO LTD (JP) 1994-10-26 EP disclosed
EP-0613468-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS Pharmacia & Upjohn Aktiebolag (SE) 1994-09-07 EP disclosed
CN-1088918-A The salicylic acid compounds of new replacement KABI PHARMACIA AB (SE) 1994-07-06 CN disclosed
US-5302718-A Used for treating autoimmune diseases KABI PHARMACIA AB (SE) 1994-04-12 US disclosed
WO-1993010094-A1 NOVEL SUBSTITUTED SALICYCLIC ACIDS KABI PHARMACIA AB (SE) 1993-05-27 WO disclosed
US-5194655-A POLYMERIZABLE CARBONATES HAVING ETHYLENIC AND ACETYLENIC FUNCTIONS NIPPON PAINT COMPANY, LIMITED (JP) 1993-03-16 US disclosed
EP-0457332-A1 Polymerizable carbonates having ethylenic and acetylenic functions NIPPON PAINT CO., LTD. (JP) 1991-11-21 EP disclosed
US-4812575-A ULTRAVIOLET RADIATION ABSORBER THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) 1989-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10377692-B2 Photoresist composition C1R, C1S, F12 PTGS2 1108/4885CA12 1919/4885CA1 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.